The challenge
With its lead indication set, the client needed to prioritize additional indications and sequence them for Phase 3 trials based on indication fit, regional attractiveness, feasibility, and strategic fit, starting from a universe of roughly 100 candidate indications.
The solution
BCE developed a full list of addressable indications and vetted it down to a shortlist of roughly 22. BCE then conducted primary and secondary research to size the addressable market by indication and region, while also assessing clinical need, competitive dynamics, and pricing expectations. This research fed revenue projections based on adoption curves, pricing, and share gain, alongside development cost estimates covering clinical trials, registration, pre-launch marketing, and salesforce investment.
The results
BCE delivered a global, Excel-based market, revenue, and cost projection tool with distinct assumptions by indication and region, plus base, upside, and downside cases. The client used this tool to sequence indications and regions to establish and sustain premium pricing while maximizing revenue, ROI, and NPV.
